CISH and endocrine system disorder: Six of these SOCs identified were not mentioned in the drug labeling information for upadacitinib: renal and urinary system (1.09%), reproductive and breast diseases (1.14%), ear and labyrinth disorders (0.57%), psychiatric disease (0.57%), blood and lymphatic system disorders (0.57%), and endocrine disorders (0.57%).